- Home
- BIIB vs TPR Comparison
BIIB vs TPR Comparison
Compare BIIB & TPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TPR
- Stock Information
- Founded
- BIIB 1978
- TPR 1941
- Country
- BIIB United States
- TPR United States
- Employees
- BIIB N/A
- TPR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TPR Apparel
- Sector
- BIIB Health Care
- TPR Consumer Discretionary
- Exchange
- BIIB Nasdaq
- TPR Nasdaq
- Market Cap
- BIIB 18.8B
- TPR 17.5B
- IPO Year
- BIIB 1991
- TPR 2000
- Fundamental
- Price
- BIIB $127.50
- TPR $101.61
- Analyst Decision
- BIIB Buy
- TPR Buy
- Analyst Count
- BIIB 27
- TPR 18
- Target Price
- BIIB $188.17
- TPR $85.11
- AVG Volume (30 Days)
- BIIB 1.2M
- TPR 3.9M
- Earning Date
- BIIB 07-31-2025
- TPR 08-14-2025
- Dividend Yield
- BIIB N/A
- TPR 1.38%
- EPS Growth
- BIIB 26.39
- TPR 0.55
- EPS
- BIIB 10.12
- TPR 3.79
- Revenue
- BIIB $9,816,400,000.00
- TPR $6,878,600,000.00
- Revenue This Year
- BIIB N/A
- TPR $5.39
- Revenue Next Year
- BIIB N/A
- TPR $2.15
- P/E Ratio
- BIIB $12.69
- TPR $26.85
- Revenue Growth
- BIIB 1.59
- TPR 2.67
- 52 Week Low
- BIIB $110.04
- TPR $35.23
- 52 Week High
- BIIB $236.48
- TPR $101.79
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- TPR 82.06
- Support Level
- BIIB $132.37
- TPR $84.39
- Resistance Level
- BIIB $137.84
- TPR $89.18
- Average True Range (ATR)
- BIIB 4.12
- TPR 2.54
- MACD
- BIIB 0.01
- TPR 1.22
- Stochastic Oscillator
- BIIB 25.82
- TPR 98.81
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TPR Tapestry Inc.
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounts for about 80% of its sales and more than 90% of its operating profit. Coach products are sold through 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade, which generated 54% of its sales from handbags in fiscal 2024. Kate Spade is known for its colorful patterns and graphics. Meanwhile, Tapestry's smallest brand, luxury footwear maker Stuart Weitzman, is set to be sold to Caleres in the summer of 2025.